Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Why do women avoid using public restrooms?

31 Jul 2020

A recent study has found that a lot of women avoid public restroom over concerns of cleanliness, privacy, and availability of amenities, and many of those who normally limit their use of these restrooms more frequently report unhealthy toilet behaviours and lower urinary tract conditions.

In total, 6,004 women participated in this study, of whom 26 percent reported limiting public restroom use most or all of the time and were more concerned with cleanliness than those who did not limit public restroom use.

In addition, these women reported using nonsitting positions when away from home and holding their urine to avoid public restroom. They also reported higher International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) scores, more frequent overactive bladder, and fewer than seven voids a day.

“These findings will help guide future research and inform public policy and bladder health awareness,” the authors said.

This cross-sectional study sought to identify why women avoid public restrooms and the associations of lower urinary tract symptoms and toileting behaviours.

A convenience sample of US women was recruited between October and December 2017 to complete a cross-sectional, anonymous questionnaire regarding public restroom use, lower urinary tract symptoms (using ICIQ-FLUTS), and toileting behaviour (using Web-Based Toileting Behaviour). The authors then compared women who reported limiting use of public restroom all or most of the time with those who did not limit or did so occasionally or sometimes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.